Clinical gene signature-based human cell culture model and uses thereof
US10988737B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Apr 28, 2016 |
| Grant date | Apr 27, 2021 |
| Priority date | — |
| Expiry date | Apr 28, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/085
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.